TipRanks
Advertisement
Advertisement

NGEN Stock Latest News

NervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year
The FlyNervGen Pharma reports Q2 EPS (C$0.37) vs. (C$0.13) last year
1M ago
NGEN
NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position
PremiumCompany Announcements
NervGen Pharma Posts Larger Q2 2026 Loss but Strengthens Cash Position
1M ago
6K
NGEN
NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
PremiumThe Fly
NervGen Pharma price target lowered to $15 from $18 at H.C. Wainwright
2M ago
NGEN
NervGen Pharma initiated with an Outperform at Leerink
PremiumThe Fly
NervGen Pharma initiated with an Outperform at Leerink
2M ago
NGEN
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners
PremiumCompany Announcements
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners
3M ago
6K
NGEN
NervGen Pharma initiated with a Buy at TD Cowen
PremiumThe FlyNervGen Pharma initiated with a Buy at TD Cowen
3M ago
NGEN
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
Premium
Company Announcements
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
4M ago
6K
NGEN
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
Premium
Company Announcements
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
4M ago
NGEN
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
PremiumCompany Announcements
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
4M ago
6K
NGEN
NervGen Pharma files $250M mixed securities shelf
PremiumThe Fly
NervGen Pharma files $250M mixed securities shelf
4M ago
NGEN
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
PremiumThe Fly
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
4M ago
NGEN
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
PremiumCompany Announcements
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
4M ago
6K
NGEN
NervGen Pharma 24M share Spot Secondary priced at $2.50
PremiumThe FlyNervGen Pharma 24M share Spot Secondary priced at $2.50
4M ago
NGEN
NervGen Pharma secondary being re-offered at $2.50 per share
Premium
The Fly
NervGen Pharma secondary being re-offered at $2.50 per share
4M ago
NGEN
NervGen Pharma announces common share offering, no amount given
Premium
The Fly
NervGen Pharma announces common share offering, no amount given
4M ago
NGEN
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
PremiumCompany Announcements
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
4M ago
6K
NGEN
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
PremiumThe Fly
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
4M ago
NGEN
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
PremiumCompany Announcements
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
4M ago
6K
NGEN
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
PremiumCompany Announcements
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
5M ago
6K
NGEN
NervGen Pharma appoints Keith Vendola as CFO
PremiumThe FlyNervGen Pharma appoints Keith Vendola as CFO
5M ago
NGEN
NervGen Pharma initiated with a Buy at H.C. Wainwright
Premium
The Fly
NervGen Pharma initiated with a Buy at H.C. Wainwright
5M ago
NGEN
NervGen Pharma initiated with a Buy at Lucid Capital
Premium
The Fly
NervGen Pharma initiated with a Buy at Lucid Capital
5M ago
NGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >